KyungDong Pharm home
Prescription Medicines

Rebamide Tab.

Product Category
Peptic ulcer medication
Active Ingredients
rebamipide
Appearance
A white, round, film-coated tablet.
Reimbursement Code
648100450
View Regulatory Information on the MFDS Portal ↗
1. Composition and Strength : 1 tablet
- Active ingredient: Rebamipide (JP) · · · · · · · · 100mg
- Additives (animal-derived ingredients): Lactose hydrate (cow, milk)
- Other additives: Magnesium stearate, Opadry White (03B28796), low-substituted hydroxypropyl cellulose, colloidal silicon oxide, hydroxypropyl cellulose

2. Effectiveness
1. Stomach ulcer
2. Improvement of gastric mucosal lesions (erosion, bleeding, redness, edema) of the following diseases: acute gastritis, acute exacerbation of chronic gastritis

3. Dosage and dosage
Adults: Rebamipide is administered orally at a dose of 100 mg three times a day. However, in case of stomach ulcers, administer in the morning, evening and before bedtime.

4. Precautions for use
1. Do not administer to the following patients.
1) Patients with a history of hypersensitivity to the ingredients of this drug
2) Since this drug contains lactose, it should not be administered to patients with genetic problems such as galactose intolerance, Lapp lactase deficiency, or glucose-galactose malabsorption.

2. Adverse reactions
Here, ‘rarely’ means less than 0.1%, ‘sometimes’ means less than 0.1 to 5%, and no expression means more than 5% or unknown frequency.
1) Serious adverse reactions
(1) Shock and anaphylaxis-like symptoms (frequency unknown): Shock and anaphylaxis-like symptoms may occur, so observe thoroughly and if abnormalities are recognized, stop administration and take appropriate measures.
(2) Decreased white blood cell count (rare), decreased platelet count (frequency unknown): Decreased white blood cell count and platelet count may occur, so observe thoroughly, and if abnormalities are recognized, stop administration and take appropriate measures.
(3) Liver dysfunction (rare), jaundice (frequency unknown): Liver dysfunction and jaundice accompanied by elevations in AST, ALT, γ-GTP, and ALP may occur. Therefore, sufficient observation should be conducted, and if abnormalities are recognized, administration should be discontinued and appropriate measures should be taken.
2) Other adverse reactions
(1) Hypersensitivity reaction: Hypersensitivity reactions such as urticaria, rarely rash, itching, and eczema may occur. In such cases, discontinue administration.
(2) Mental nervous system: Paralysis, dizziness, and drowsiness may occur.
(3) Digestive system: Dry mouth, rarely constipation, abdominal distension, diarrhea, nausea, vomiting, heartburn, abdominal pain, burping, and abnormal taste may occur.
(4) Liver: In rare cases where transaminase levels such as AST, ALT, γ-GTP, and ALP are significantly elevated, or when fever or rash occurs simultaneously, administration should be discontinued and appropriate measures should be taken.
(5) Blood system: decreased platelets, sometimes leukocyte fractionation, decreased fractional nuclear cells, elevated lymphocytes, and rarely decreased white blood cells and decreased granulocytes.
(6) Others: Mammary gland swelling, breast pain, gynecomastia, induction of milk secretion, palpitations, fever, facial flushing, numbness of the tongue, cough, difficulty breathing, hair loss, or in rare cases, menstrual abnormalities, increased BUN, edema, and sensation of a foreign body in the pharynx may occur.

3. Administration to pregnant and lactating women
1) Since the safety of administration during pregnancy has not been established, it should be administered to pregnant women or women who may be pregnant only when the therapeutic benefits are judged to outweigh the risks.
2) In animal experiments, it has been reported that the drug passes into breast milk, so avoid breastfeeding when administering to a nursing mother.

4. Administration to children
Safety for low birth weight infants, newborns, infants, and children has not been established (there is little experience with use).

5. Administration to elderly people
There is no difference in the types and occurrence rates of adverse reactions identified in elderly people compared to non-elderly people, but elderly people generally have reduced physiological functions, so they should be careful of adverse reactions such as digestive symptoms.

6. Storage and handling precautions
1) Keep out of reach of children.
2) Be careful because changing it into another container may cause an accident or is undesirable in terms of maintaining quality.

7. Pharmaceutical equivalence test information (Note 1)
A. In a 2 × 2 crossover study, healthy adults received a single oral dose of one tablet each of the test product, Rebamiron tablets (UN Life Science Co., Ltd.), and the reference product, Mucosta tablets (Korea Otsuka Pharmaceutical Co., Ltd.), under fasting conditions. Plasma rebamipide concentrations were measured in 48 participants. Statistical analysis of log-transformed AUCt and Cmax values showed that the 90% confidence intervals for the differences in means were within log 0.8 to log 1.25, demonstrating bioequivalence.
※ Table: Refer to attached document
(Note 1) This drug was manufactured by U& Life Science Co., Ltd. using the same raw materials as Revamiron Tablet (Rebamipide) and the entire process was outsourced to U& Life Science Co., Ltd. using the same manufacturing method.

5. How to save
Store in a light-proof sealed container at room temperature (1~30℃)

6. Packaging unit
30 tablets/bottle, 500 tablets/bottle

7. Period of use
36 months from date of manufacture

Product Updates

Total 2items

No.Product NameDetailsDate of ChangeDownload
2Rebamide Tab.Levamide tablets (effectiveness, dosage, directions for use...2012.12.31HWPLevamide tablet_Permission change order.hwp
1Rebamide Tab.Levamide tablets (precautions for use)2009.10.06HWPChange in Levamide tablets (precautions for use) (2009.10.06).hwp